Many monotherapies and combination therapies with anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies have not shown promising therapeutic effects or gained approval for PCa; nonetheless, significant effectiveness has been observed in some cases. The gene discussed is PDCD1; the disease is posterior cortical atrophy.